Syneos Health
Syneos Health
A fully integrated biopharmaceutical solutions organization providing clinical development and commercialization services to life sciences companies.
About
Pricing
View pricing page ↗What does Syneos Health do?
Syneos Health is a global biopharmaceutical solutions organization that combines contract research organization (CRO) and contract commercial organization (CCO) capabilities. It provides end-to-end services, including clinical trials, medical affairs, and commercialization strategies, to help pharmaceutical, biotechnology, and medical device companies accelerate the delivery of therapies to patients.
What is Syneos Health's valuation?
StartupHub estimates Syneos Health's effective valuation at $44.4B (range $34.8B to $164.1B, 58% confidence), based on comparable companies in the sector.
Where is Syneos Health headquartered?
Syneos Health is headquartered in Morrisville, United States.
When was Syneos Health founded?
Syneos Health was founded in 2017.
What industry does Syneos Health operate in?
Syneos Health operates in Biotechnology, Pharmaceutical, Healthcare, Clinical Research.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.